Fig. 1

Prolactin receptor is overexpressed in hematological malignancies. A PRLR (211917_s_at) and PRL (205445_at) mRNA expression in healthy blood donor cells (grey) and AML cells (red) from the GSE13159 database. Ns, not significant; **p < 0.01 (unpaired t test). B PRLR surface expression in CD45⁺ cell population of healthy donors (PB-MNCs n = 10, and HSPC n = 3, grey), AML (n = 59, red), and MDS (n = 39, blue) patient cells were analysed by flow cytometry *p < 0.05 (one-way ANOVA, Dunnett’s multiple comparison test). C PRLR protein expression in AML samples (n = 2) and healthy blood donor cells (n = 2) were analysed by Western Blot; GAPDH was used as loading control. D PRLR surface expression in different hematopoietic subpopulations of healthy blood cells (n = 10, grey) and in CD45⁺ cell population of neoplastic blood cells [AML (n = 59, red) and MDS (n = 39, blue)] were analysed as in B. E PRLR surface expression in a panel of cell lines derived from hematological malignancies (n = 19) and classified by phenotype [myeloid (orange), lymphoid B (green) and lymphoid T (blue)] analysed as in B. Bars represent the mean ± SEM (duplicates)